Suicidal Ideation, Behaviors Not Increased With GLP-1 RAs for Seniors With T2D
By Elana Gotkine HealthDay Reporter
TUESDAY, July 16, 2024 -- For older adults with type 2 diabetes (T2D), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is not associated with a significantly increased risk for suicidal ideation and behaviors, according to a study published online July 16 in the Annals of Internal Medicine.
Huilin Tang, from the University of Florida College of Pharmacy in Gainesville, and colleagues examined the association between GLP-1 RAs versus sodium-glucose cotransporter 2 inhibitors (SGLT2is) or dipeptidyl peptidase 4 inhibitors (DPP4is) and the risk for suicidal ideation and behaviors among older adults with T2D in two target trial emulation studies using U.S. national Medicare administrative data from January 2017 to December 2020. In each pairwise comparison, new GLP-1 RA users were matched in a 1:1 ratio on propensity score to new users of SGLT2is or DPP4is.
Overall, 21,807 pairs of patients treated with a GLP-1 RA versus an SGLT2i and 21,402 pairs of patients treated with a GLP-1 RA versus a DPP4i were included in the analyses. The researchers found that the hazard ratios of suicidal ideation and behaviors were not significantly different for GLP-1 RAs versus SGLT2is (1.07; 95 percent confidence interval, 0.80 to 1.45) or for GLP-1 RAs versus DPP4is (0.94; 95 percent confidence interval, 0.71 to 1.24).
"Among Medicare beneficiaries with T2D, this study found no clear increased risk for suicidal ideation and behaviors with GLP-1 RAs, although estimates were imprecise and a modest adverse effect could not be ruled out," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Aging Into Medicare Tied to Higher Drug Costs for People With Diabetes
WEDNESDAY, July 17, 2024 -- As people with diabetes age into Medicare, they face increased quarterly out-of-pocket costs for medication, according to a study published online July...
Extended-Release Oral Ketamine Effective for Treatment-Resistant Depression
WEDNESDAY, July 17, 2024 -- For patients with treatment-resistant depression, racemic ketamine, given as an extended-release tablet (R-107), administered orally, is effective...
Psychological Risks Increased for Transgender Youth at Gender Identity Milestones
MONDAY, July 15, 2024 -- Transgender youth have an increased risk for attempting suicide or running away from home in association with gender identity milestones, with the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.